Select: All | None

Select: All | None

Select: All | None

TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS

University of Calgary

ABSTRACT In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neurological disease is multiple sclerosis (also referred to as "MS"). - 78 -

APELIN PEPTIDES AND USES THEREOF

University of Alberta

The disclosure relates to modified apelin polypeptides having increased stability against kaliikrein, NEP and ACE2 degradation and/or potency relative to the native apelin-13 and apelin-17 polypeptides. Embodiments also disclose methods of using the polypeptides for treating cardiovascular disorders.

METHODS OF FORMING CARBENE-FUNCTIONALIZED COMPOSITE MATERIALS

Queen's University

Deposition of carbene monolayers that excluded starting anions, such as iodide ions, has been achieved. Anions such as iodide are a typical contaminant in carbene hydrogen carbonate salts when synthesized using the state-of-the-art method. A method is described for eliminating substantially all starting anion (e.g., iodide) contamination from the monolayer. Air stable, purified carbenes precursors were used to deposit an intact monolayer on the surface of some industrially relevant metals....

OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL

PRESIDENT AND FELLOWS OF HARVARD COLLEGE, University of Alberta

Provided herein are variants of an archaerhodopsin useful for application such as optical measurement of membrane potential. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, cells comprising the polynucleotides, and cells comprising the polypeptides; and methods of using the variants.

BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS

British Columbia Cancer Agency, University of British Columbia

Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION

University of British Columbia

Methods and devices are provided herein for identifying a cell population comprising an effector cell that exerts an extracellular effect. In one embodiment the method comprises retaining in a microreactor a cell population comprising one or more effector cells, wherein the contents of the microreactor further comprise a readout particle population comprising one or more readout particles, incubating the cell population and the readout particle population within the microreactor, assaying...

METHODS, KITS AND COMPOSITIONS FOR PHENOTYPING PANCREATIC DUCTAL ADENOCARCINOMA BEHAVIOUR BY TRANSCRIPTOMICS

CENTRE HOSPITALIER UNIVERSITAIRE DE QUEBEC, Centre National de la Recherche Scientifique, INSTITUT JEAN PAOLI & IRENE CALMETTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ D'AIX-MARSEILLE

An in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of: a1) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group of PDAC marker genes consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2;...

USE OF FLUORINATED CYCLIC DINUCLEOTIDES AS ORAL VACCINE ADJUVANTS

Brock University, National Research Council Canada

Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.

A METHOD OF VACCINATION COMPRISING A HISTONE DEACETYLASE INHIBITOR

McMaster University, Ottawa Hospital Research Institute

A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.

METHOD AND SYSTEM FOR ABO ANTIBODY DETECTION AND CHARACTERIZATION

University of Alberta

The present application discloses a system and method for ABO antibody detection and characterization that can provide an alternative means for assessment and management of ABO-incompatible and ABO- compatible transplants. The method and system comprises determining an anti-ABO blood group antigen subtype antibody profile of a subject using a biological sample from the subject. The method and system can be used to evaluate the suitability of a donor blood or tissue product for a recipient...